Therefore, owing to their groundbreaking chemical structure and extraordinary anti-MM activity, 2-iminobenzimidazoles (such as compounds 5b and 5d) can be identified as novel potent c-Myc inhibitors for the treatment of multiple myeloma. This evidence concerns the gene MYC and plasma cell myeloma.